Table 3.
Univariate and multivariate survival analyses of the mRNA expression of CYB5R2, MME, and SERINA9 in CD5+ DLBCL.
| Variables | Univariate analysis | Multivariate analysis | ||
|---|---|---|---|---|
| P | HR (95% CI) | P | HR (95% CI) | |
| OS | ||||
| CYB5R2 | 0.037 | 4.368 (0.996-19.742) | 0.221 | 5.242 (0.369-74.376) |
| MME | 0.001 | 0.159 (0.047-0.547) | 0.002 | 0.038 (0.005-0.290) |
| SERPINA9 | 0.036 | 0.152 (0.047-0.541) | 0.021 | 0.028 (0.001-0.583) |
| MYC+/BCL2+ | 0.392 | 1.592 (0.550-4.592) | 0.040 | 4.951 (1.078-22.741) |
| MYC+/BCL6+ | 0.612 | 0.755 (0.251-2.267) | 0.707 | 0.567 (0.029-10.908) |
| MYC rearrangement | 0.378 | 0.041 (0.000-50.398) | 0.984 | 0.000 (0.000) |
| IPI (>3) | 0.178 | 2.171 (0.718-6.562) | 0.520 | 1.608 (0.378-6.845) |
| MCD vs. Non-MCD | 0.357 | 1.675 (0.559-5.023) | 0.746 | 1.434 (0.162-12.731) |
| ABC vs. Non-ABC | 0.365 | 1.684 (0.526-5.391) | 0.039 | 7.430 (1.102-50.908) |
| PFS | ||||
| CYB5R2 | 0.042 | 3.489 (0.976-12.480) | 0.791 | 1.276 (0.211-7.729) |
| SERPINA9 | 0.053 | 0.260 (0.093-0.0728) | / | |
| MME | 0.003 | 0.222 (0.076-0.649) | 0.003 | 0.156 (0.045-0.538)) |
| MYC+/BCL2+ | 0.295 | 1.698 (0.630-4.579) | 0.200 | 1.980 (0.697-5.625) |
| MYC+/BCL6+ | 0.699 | 0.819 (0.296-2.268) | 0.851 | 0.864 (0.315-6.361) |
| MYC rearrangement | 0.420 | 0.433 (0.057-3.307) | 0.154 | 0.207 (0.024-1.801) |
| IPI>3 | 0.121 | 2.230 (0.810-6.139) | 0.650 | 1.417 (0.515-12.094) |
| MCD vs. Non-MCD | 0.405 | 1.544 (0.556-4.294) | 0.523 | 1.476 (0.447-4.870) |
| ABC vs. Non-ABC | 0.410 | 1.564 (0.540-4.531) | 0.499 | 1.580 (0.420-5.949) |
OS, overall survival; PFS, progression-free survival; IPI, International Prognostic Index; ABC, activated B-cell like. The P values that <0.05 were presented in bold font.